Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

NCT02364596

Last updated date
Study Location
Broward Research Group
Hollywood, Florida, 33024, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Staphylococcal Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-64 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject has been informed of all pertinent aspects of the study. 2. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures, including daily completion of the e-diary for 10 days after study vaccination. 3. Healthy male and female subjects, aged 18 to <65 years at enrollment, as determined by medical history, physical examination, and the clinical judgment of the investigator to be eligible for the study. Subjects with preexisting chronic medical conditions determined to be stable may be included. 4. Male and female subjects of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception throughout the study. 5. Subject must be able to be contacted by telephone during study participation.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Unstable chronic medical condition or disease requiring significant
change in therapya or hospitalization for worsening disease within 3 months before receipt
of investigational product. 2. Serious chronic medical disorders including metastatic
malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental
oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac
disease, or any other disorder that in the investigator's opinion precludes the subject
from participating in the study. 3. Congenital or acquired immunodeficiency disorder,
rheumatologic disorder, or other illness requiring chronic treatment with known
immunosuppressant medications, including monoclonal antibodies, within the year prior to
enrollment or the use of systemic corticosteroids (equivalent of ≥10 mg/day of prednisone)
for >14 days within 30 days prior to study enrollment. 4. History of leukemia, lymphoma, or
underlying bone marrow disorder (eg, myelodysplasia, myeloma, myeloproliferative disorder)
or history of bone marrow transplant. 5. Malignancy that required treatment with
chemotherapy, immunotherapy, radiation therapy, or other antineoplastic target therapies
within 24 months prior to study enrollment. 6. Any infection proven or suspected to be
caused by S. aureus within 6 months preceding study vaccination. 7. Previous administration
of S. aureus vaccine or S. aureus/Candida vaccine. 8. Any contraindication to vaccination
or vaccine components, including previous anaphylactic reaction to any vaccine or
vaccine-related components. 9. Bleeding diathesis or condition associated with prolonged
bleeding time that would contraindicate intramuscular injection. 10. Donation of blood
volume of 250 mL or greater (excluding protocol-required blood collection) or donation of
plasma within 3 months prior to enrollment through conclusion of the study. 11. Receipt of
blood products or immunoglobulins (including monoclonal antibodies) within 6 months before
enrollment or anticipated through conclusion of the subject's participation. 12. Subjects
who are investigational site staff members directly involved in the conduct of the study
and their family members, site staff members otherwise supervised by the investigator, or
subjects who are Pfizer employees directly involved in the conduct of the study. 13.
Participation in other studies involving investigational drug(s) (Phases 1-4) within 30
days before the current study begins and/or during study participation. Participation in
observational studies is permitted. 14. Pregnant female subjects; breastfeeding female
subjects; male subjects with partners currently pregnant; male and female subjects of
childbearing potential and at risk for pregnancy who are unwilling or unable to use a
highly effective method of contraception as outlined in this protocol for the duration of
the study. 15. Residence in a nursing home or long-term care facility or requirement for
semiskilled nursing care. An ambulatory subject who is a resident of a retirement home or
village is eligible for the trial. 16. Subjects with known active disease with human
immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV). 17.
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality
that may increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the subject inappropriate for entry into this
study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Staphylococcal InfectionsDrug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)
NCT00666276
ALL GENDERS
0+
years
MULTIPLE SITES
Staphylococcal InfectionsSA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults
NCT02492958
  1. Sumida-ku, Tokyo
  2. Fukuoka,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Staphylococcal InfectionsEvaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
NCT02364596
  1. Hollywood, Florida
  2. South Miami, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Staphylococcal InfectionsEvaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
NCT01643941
  1. Hollywood, Florida
  2. South Miami, Florida
  3. Overland Park, Kansas
  4. Cary, North Carolina
  5. Cincinnati, Ohio
  6. Nashville, Tennessee
  7. Austin, Texas
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
Official Title  ICMJE A Phase 1, Single-arm, Open-label Study To Confirm The Safety, Tolerability, And Immunogenicity Of A 4-antigen Staphylococcus Aureus Vaccine (sa4ag) In Healthy Adults Aged 18 To <65 Years
Brief Summary The purpose of this study is to evaluate the safety and immunogenicity of a single vaccination of an investigational vaccine against Staphylococcus aureus (SA4Ag) in healthy adults aged 18 to <65 years.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Staphylococcal Infections
Intervention  ICMJE
  • Biological: SA4Ag vaccine
    Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.
  • Procedure: Blood sample
    Blood for immunogenicity will be collected from all subjects at various timepoints.
Study Arms  ICMJE Experimental: 1
SA4Ag vaccine
Interventions:
  • Biological: SA4Ag vaccine
  • Procedure: Blood sample
Publications * Begier E, Seiden DJ, Patton M, Zito E, Severs J, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, Gurtman A. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Vaccine. 2017 Feb 22;35(8):1132-1139. doi: 10.1016/j.vaccine.2017.01.024. Epub 2017 Jan 28.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 10, 2015)
100
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE February 2015
Actual Primary Completion Date February 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria: 1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject has been informed of all pertinent aspects of the study. 2. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures, including daily completion of the e-diary for 10 days after study vaccination. 3. Healthy male and female subjects, aged 18 to <65 years at enrollment, as determined by medical history, physical examination, and the clinical judgment of the investigator to be eligible for the study. Subjects with preexisting chronic medical conditions determined to be stable may be included. 4. Male and female subjects of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception throughout the study. 5. Subject must be able to be contacted by telephone during study participation.

Exclusion Criteria: 1. Unstable chronic medical condition or disease requiring significant change in therapya or hospitalization for worsening disease within 3 months before receipt of investigational product. 2. Serious chronic medical disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that in the investigator's opinion precludes the subject from participating in the study. 3. Congenital or acquired immunodeficiency disorder, rheumatologic disorder, or other illness requiring chronic treatment with known immunosuppressant medications, including monoclonal antibodies, within the year prior to enrollment or the use of systemic corticosteroids (equivalent of ?10 mg/day of prednisone) for >14 days within 30 days prior to study enrollment. 4. History of leukemia, lymphoma, or underlying bone marrow disorder (eg, myelodysplasia, myeloma, myeloproliferative disorder) or history of bone marrow transplant. 5. Malignancy that required treatment with chemotherapy, immunotherapy, radiation therapy, or other antineoplastic target therapies within 24 months prior to study enrollment. 6. Any infection proven or suspected to be caused by S. aureus within 6 months preceding study vaccination. 7. Previous administration of S. aureus vaccine or S. aureus/Candida vaccine. 8. Any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components. 9. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection. 10. Donation of blood volume of 250 mL or greater (excluding protocol-required blood collection) or donation of plasma within 3 months prior to enrollment through conclusion of the study. 11. Receipt of blood products or immunoglobulins (including monoclonal antibodies) within 6 months before enrollment or anticipated through conclusion of the subject's participation. 12. Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees directly involved in the conduct of the study. 13. Participation in other studies involving investigational drug(s) (Phases 1-4) within 30 days before the current study begins and/or during study participation. Participation in observational studies is permitted. 14. Pregnant female subjects; breastfeeding female subjects; male subjects with partners currently pregnant; male and female subjects of childbearing potential and at risk for pregnancy who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study. 15. Residence in a nursing home or long-term care facility or requirement for semiskilled nursing care. An ambulatory subject who is a resident of a retirement home or village is eligible for the trial. 16. Subjects with known active disease with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV). 17. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 64 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02364596
Other Study ID Numbers  ICMJE B3451015
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP